Tuesday’s agreement will see shareholders receive 0.6539 Akzo Nobel shares for each Axalta common share, giving an equity value of €7.9 billion, according to a Bloomberg calculation. Akzo Nobel shareholders will own 55% of the combined company, which will move its listing to New York.
